newsfilter
← Latest News
GlobeNewswire·

NeOnc Raises $15 Million At Market Adding Fuel to the Strong NEO100 Data

NTHI
  • NeOnc Technologies Holdings (NASDAQ: NTHI) announced a $15 million registered direct offering priced at-market under Nasdaq rules, involving 3.57 million shares or pre-funded warrants plus warrants for another 3.57 million shares at a $4.20 exercise price.
  • The financing closes tomorrow subject to customary conditions & includes new & existing healthcare-focused institutional investors.
  • The deal structure avoids deeply discounted stock issuance common in small-cap biotech, thereby reducing dilution concerns & countering short-seller arguments.
  • Positive Phase 2a data for NEO100 in IDH1-mutant glioma patients showed 48.9% six-month progression-free survival, exceeding the 20% benchmark with a p-value of 0.0047.
  • Median overall survival was 26.09 months, 86.7% of patients were alive at six months, & five of 24 patients remained on treatment.
  • NeOnc plans to request an FDA Type B meeting to discuss a potential registrational pathway for NEO100 following the small, open-label Phase 2a study.
  • The company's second candidate, NEO212, completed Phase 1 with a recommended Phase 2 dose of 610 mg & received UAE IND approvals for adult & pediatric programs alongside NEO100.
  • NEO100 is an intranasal formulation of purified perillyl alcohol designed to cross the blood-brain barrier for CNS drug delivery.
  • CEO Amir Heshmatpour purchased 15,000 shares in August for approximately $58,600, bringing his total disclosed open-market investment to over $500,000.
  • Director Thomas Chen, M.D., Ph.D. purchased 33,787 shares on August 14 & 2,472 shares on August 17.
  • The combination of institutional capital, clinical data exceeding benchmarks, upcoming FDA discussions, & significant insider buying creates a strategic setup for NeOnc.